Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19503141 | 1.00 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL17815409 | 1.00 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL19046498 | 1.00 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL20467806 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL19708237 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL25009079 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL24477218 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL17815262 | 0.93 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL21780990 | 0.93 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R | |
| SCHEMBL19709072 | 0.93 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-3804765-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3626273-B1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-12-30 | — | — | EP | disclosed |
| WO-2020236795-A2 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| EP-3458102-B1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2017-12-07 | — | — | US | disclosed |
| WO-2017201204-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017095805-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017095808-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20160122430-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | SIRT2 4097/4885SIRT1 4465/4885SIRT5 2607/4885 |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | SIRT2 4097/4885SIRT1 4465/4885SIRT5 2607/4885 |
| US-20160122430-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD47, CSGALNACT1, CSE1L | SIRT2 3559/4885SIRT1 3858/4885SIRT5 2958/4885 |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | SIRT2 4689/4885SIRT1 4857/4885SIRT5 3223/4885 |
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | SIRT2 4689/4885SIRT1 4857/4885SIRT5 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.